Management dilemma of cardiopulmonary bypass in patients with type II heparin-induced thrombocytopenia.
Saad
R A G
RA
Horn
L
L
Mankad
P S
PS
D000368:Aged; D001367:Axillary Vein; D002315:Cardiopulmonary Bypass; D005260:Female; D005343:Fibrinolytic Agents / Q000009:adverse effects*; D006325:Heart Atria; D006338:Heart Neoplasms / Q000150:complications / Q000601:surgery; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects*; D024764:Hirudin Therapy / Q000379:methods; D006801:Humans; D009232:Myxoma / Q000601:surgery; D012307:Risk Factors; D013921:Thrombocytopenia / Q000139:chemically induced*; D000078222:Tinzaparin; D020246:Venous Thrombosis / Q000209:etiology
D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D000078222:Tinzaparin